Here is my Q&A with Joe on 10/15/2019 conf call (y

Quote:

---

Steve: That was many, many years ago, and that appraisal [?] was around, what... it
was 300 million? Is that still effective or do you think it's--obviously, we
think it's a lot higher than and I could see it come a lot farther along--we have
a lot more things that are underneath--Antigen at this point, especially with
the ALTuCELL that you're going to incorporate--that's going to be
incorporated into the NGIO, right?
Joe: No, ALTuCELL will be on Generex. And then obviously, ALTuCELL will
get our oral and assets for Type 2, which has been reformulated, and that we
will get back into the clinic. But first and foremost, see the FDA on what we
could utilize from all those past trials, hopefully on safety and on efficacy
_____ [00:47:04] for Type 2s instead of Type 1s.
GENEREX_10152019
Page 14 of 28
Steve: Okay. So, what kind of value are you thinking NGIO has at this point? Are
you getting another assessment done, another appraisal done that will be
released? Or do you have a value in mind with the reverse merger and the
listing?
Joe: Certainly, Generex is putting tens upon tens upon tens of millions of dollars
into Antigen. So, there's a value on the money that we've put into the
company, as well as we have looked into rekindling the appraisals on the
platforms that we had done before. As you mentioned, it was... I believe over
300 million just on breast cancer. It is a platform technology with the IIT
platform.
So, right now, we've reached out to appraisal companies that just do pharma,
and that's going to help us establish pricing for when the company is public
come towards the end of November. So, that's a play of our initiatives, get
something like that done to establish what the value of Antigen is.
And then there are set parameters, partnerships with Big Pharma, where you
are in the clinic, that all is part of how you value especially immunotherapy
assets.

---